BIOGEN INC shareholders Q3 2023

BIOGEN INC's ticker is BIIB and the CUSIP is 09062X103. A total of 936 filers reported holding BIOGEN INC in Q3 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.2%.

BIOGEN INC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
Massachusetts Wealth Management	3,200	$822,432	0.76%
SECTORAL ASSET MANAGEMENT INC	15,012	$3,858,234	0.75%
Lindenwold Advisors, INC	4,684	$1,203,835	0.75%
GREENWOOD CAPITAL ASSOCIATES LLC	19,080	$4,903,765	0.71%
Aquila Investment Management LLC	3,000	$771,030	0.71%
Gifford Fong Associates	11,500	$2,956	0.71%
Congress Park Capital LLC	5,048	$1,297,387	0.68%
VAN ECK ASSOCIATES CORP	1,189,546	$305,725	0.67%
Alhambra Investment Management LLC	3,943	$1,013,390	0.67%
North Growth Management Ltd.	11,000	$2,933	0.65%
FORT, L.P.	911	$234,136	0.65%
Verition Fund Management LLC	212,036	$54,495,372	0.64%
Tevis Investment Management	2,440	$627,104	0.64%
CSM Advisors, LLC	28,226	$7,255	0.63%
NICOLA WEALTH MANAGEMENT LTD.	22,000	$5,654,220	0.61%
WEDGE CAPITAL MANAGEMENT L L P/NC	118,204	$30,379,610	0.60%
American Assets Investment Management, LLC	20,000	$5,140,200	0.57%
Polar Capital Holdings Plc	300,000	$77,103,000	0.57%
Trail Ridge Investment Advisors, LLC	3,270	$840,423	0.57%
Vanguard Capital Wealth Advisors	2,300	$591,123	0.55%

About BIOGEN INC

Biogen Inc. is a biotechnology company that specializes in the development and commercialization of therapies for neurological and neurodegenerative diseases. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen's most successful drug is aducanumab, which is used to treat Alzheimer's disease. The drug was approved by the FDA in June 2021, making it the first new Alzheimer's drug in nearly two decades. The approval was a major milestone for Biogen, as the drug has the potential to generate billions of dollars in revenue.

In addition to aducanumab, Biogen has a number of other drugs in its pipeline. The company is currently developing therapies for multiple sclerosis, spinal muscular atrophy, and other neurological disorders. Biogen is also investing heavily in gene therapy, which has the potential to revolutionize the treatment of genetic diseases.

Despite its success, Biogen has faced some challenges in recent years. The company's stock price has been volatile, and it has faced criticism from some investors over its drug development pipeline. However, Biogen's management team has remained committed to its mission of developing innovative therapies for patients with neurological and neurodegenerative diseases.

Overall, Biogen is a company with a strong track record of innovation and a promising future. With the approval of aducanumab and a robust pipeline of drugs in development, Biogen is well-positioned to continue making a significant impact in the biotechnology industry.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIOGEN INC's shareholders in Q3 2023. To view BIOGEN INC's shareholder history, click here.